Ecstasy (3,4-methylenedioxymethamphetamine)-induced inappropriate antidiuretic hormone secretion

Pediatric Emergency Care

Volumn 24, Issue 9, 2008, Pages 615-617

  Farah, Raymond ^a,c   Farah, Rola ^b  

^a Department of Internal Medicine F ^*  (Israel)

^b Leumit Health Care System   (Israel)

^c WESTERN GALILEE HOSPITAL   (Israel)

Author keywords

Ecstasy; Hyponatremia; Intoxication; MDMA; Methylenedioxymethamphetamine; SIADH

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BICARBONATE; CHLORIDE; CREATININE; ELECTROLYTE; GLUCOSE; POTASSIUM; SODIUM; PSYCHEDELIC AGENT;

ADOLESCENT; ANXIETY; ARTICLE; BLOOD PRESSURE; BREATHING RATE; BRUXISM; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CONCENTRATION (PARAMETERS); CONFUSION; CREATININE URINE LEVEL; DEHYDRATION; DISORIENTATION; ELECTROCARDIOGRAM; EMERGENCY WARD; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; FLUID INTAKE; FLUSHING; GLUCOSE BLOOD LEVEL; GRAM STAINING; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; MASS FRAGMENTOGRAPHY; MASSETER MUSCLE; MENTAL DISEASE; MICROSCOPY; NEUROLOGIC EXAMINATION; PATIENT TRANSPORT; PULSE RATE; RECTUM TEMPERATURE; RESTLESSNESS; SCREENING; SKIN TURGOR; SLURRED SPEECH; SODIUM URINE LEVEL; SOMNOLENCE; STUPOR; UREA BLOOD LEVEL; CHEMICALLY INDUCED DISORDER; SCHWARTZ BARTTER SYNDROME;

ADOLESCENT; FEMALE; HALLUCINOGENS; HUMANS; INAPPROPRIATE ADH SYNDROME; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE;

EID: 60749127079     PISSN: 07495161     EISSN: None     Source Type: Journal    
DOI: 10.1097/PEC.0b013e3181850c91     Document Type: Article

References (30)

1. Drug Trafficking in the United States. US Drug Enforcement Agency; 2001. Available online at: http://www.dea.gov/pubs/international/ foreign.html.
2. Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4 methy-lenedioxymethamphetamine in recreational users. Neuropharmacology. 1988;1:272-277.
3. Hermle L, Spitzer M, Brochart D, et al. Psychological effects of MDE in normal subjects. Are enactogens a new class of psychoactive agents? Neuropsychopharmacology. 1993;8:171-176.
4. Schwartz RH, Miller NS. MDMA (Ecstasy) and the rave: a review. Pediatrics. 1997;100:705-708.
5. Cloud J. The lure of Ecstasy. Time. 2000;155:62-74.
6. Parrott AC, Lasky J. Ecstasy (MDMA) effects upon mood and cognition before, during, and after a Saturday night dance. Psychopharmacology. 1998;139:261-268.
7. Pallanti S, Mazzi D. MDMA (Ecstasy) precipitation of panic disorder. Biol Psychiatry. 1992;32:91-95.
8. Dar KJ, McBrien ME. MDMA induced hyperthermia: report of a fatality and review of current therapy. Intensive Care Med. 1996;22:995-996.
9. Halachanova V, Sansone RA, mcDonald S. Delayed rhabdomyolysis after Ecstasy use. Mayo Clin Proc. 2001;76:112-113.
10. Andreu V, Mas A, Bruguera M, et al. Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol. 1998;29:394-397.
11. Fahal IF, Sallomi DF, Yaqoob M, et al. Acute renal failure after Ecstasy. Br Med J. 1992;305:29.
12. O'Connor A, Cluroe A, Cough R, et al. Death from hyponatremia-induced cerebral oedema associated with MDMA ("Ecstasy") use. N Z Med J. 1999;112:255-256.
13. Ajaelo I, Koenig K, Snoey E. Severe hyponatremia and inappropriate antidiuretic hormone secretion following Ecstasy use. Acad Emerg Med. 1998;5:839-840.
14. Gledhill JA, Moore DF, Bell D, et al. Subarachnoid haemorrhage associated with MDMA abuse. J Neurol Neurosurg Psychiatry. 1993; 56:1036-1037.
15. Manchanada S, Connolly MJ. Cerebral infarction in association with Ecstasy abuse. Postgrad Med J. 1993;69:874-875.
16. Suarez RV, Riemersma R. "Ecstasy" and sudden cardiac death. Am J Forensic Med Pathol. 1988;9:339-341.
17. Demirkiran M, Janovic J, Dean JM. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol. 1996;19:157-164.
18. Ricaurte GA, Forno LS, Wilson MA, et al. 3,4 Methylenedioxymetham- phetamine selectively damages central serotonergic neurons in non-human primates. JAMA. 1988;260:51-55.
19. Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with 3,4- methylenedioxymethamphetamine 7 years previously: factors influencing abnormal recovery. J Neurosci. 1999;19:5096-5107.
20. Cohen RS. Adverse symptomatology and suicide associated with the use of methylenedioxymethamphetamine (MDMA; "Ecstasy"). Biol Psychiatry. 1996;39:819-820.
21. Krystal JH, Price LH, Opsahl C, et al. Chronic 3,4-methylenedioxyme- thamphetamine (MDMA) use: effects on mood and neuropsychological function. Am J Drug Alcohol Abuse. 1992;18:331-341.
22. Kish SJ, Furukawa Y, Ang L, et al. Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user. Neurology. 2000;55:294-296.
23. Tuchtenhagen F, Daumann J, Norra C, et al. High intensity dependence of auditory evoked dipole source activity indicates decreased serotoner-gic activity in abstinent Ecstasy (MDMA) users. Neuropsychopharma-cology. 2000;22:608-617.
24. McCann UD, Eligushvili V, Ricaurte GA. 3,4-Methylenedioxymetham-phetamine ("Ecstasy")-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology. 2000;42:11-16.
25. Gomez-Balaguer M, Pena H, Morillas C, et al. Syndrome of inappropriate antidiuretic hormone secretion and "designer drugs"; (Ecstasy). J Pediatr Endocrinol Metab. 2000;13:437-438.
26. Cook TM. Cerebral oedema after MDMA ("Ecstasy") and unrestricted water intake. BMJ. 1996;313:689.
27. Henry JA, Fallon JK, Kicman AT, et al. Low-dose MDMA ("Ecstasy" ) induces vasopressin secretion. Lancet. 1998;351:1784.
28. Kirchner V, Silver LE, Kelley CA. Selective serotonin reuptake inhibitors and hyponatraemia: review and proposed mechanisms in the elderly. J Psychopharmacol. 1998;12:396-400.
29. Belton K, Thomas SH. Drug-induced syndrome of inappropriate antidiuretic hormone secretion. Postgrad Med J. 1999;75:509-510.
30. Maxwell DL, Polkey MI, Henry JA. Hyponatremia and catatonic stupor after taking Ecstasy. Br Med J. 1993;307:1399.